

Sonya Marshall-Gradisnik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11996808/publications.pdf>

Version: 2024-02-01

52
papers

982
citations

430874

18
h-index

477307

29
g-index

53
all docs

53
docs citations

53
times ranked

850
citing authors

#	ARTICLE	IF	CITATIONS
1	The prevalence of chronic fatigue syndrome/ myalgic encephalomyelitis: a meta-analysis. <i>Clinical Epidemiology</i> , 2013, 5, 105.	3.0	151
2	Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). <i>BMC Immunology</i> , 2015, 16, 35.	2.2	46
3	Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome. <i>The Application of Clinical Genetics</i> , 2016, 9, 39.	3.0	44
4	A systematic review of neurological impairments in myalgic encephalomyelitis/ chronic fatigue syndrome using neuroimaging techniques. <i>PLoS ONE</i> , 2020, 15, e0232475.	2.5	43
5	A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome. <i>Systematic Reviews</i> , 2019, 8, 279.	5.3	42
6	Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. <i>Journal of Translational Medicine</i> , 2015, 13, 299.	4.4	40
7	The adoption of chronic fatigue syndrome/myalgic encephalomyelitis case definitions to assess prevalence: a systematic review. <i>Annals of Epidemiology</i> , 2013, 23, 371-376.	1.9	37
8	Epidemiological characteristics of chronic fatigue syndrome/myalgic encephalomyelitis in Australian patients. <i>Clinical Epidemiology</i> , 2016, 8, 97.	3.0	37
9	Intra brainstem connectivity is impaired in chronic fatigue syndrome. <i>NeuroImage: Clinical</i> , 2019, 24, 102045.	2.7	37
10	A systematic review of mitochondrial abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease. <i>Journal of Translational Medicine</i> , 2020, 18, 290.	4.4	36
11	ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/âˆ™ natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. <i>Journal of Translational Medicine</i> , 2016, 14, 97.	4.4	31
12	Prevalence and characteristics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in Poland: a cross-sectional study. <i>BMJ Open</i> , 2019, 9, e023955.	1.9	30
13	Hyperintense sensorimotor T1 spin echo MRI is associated with brainstem abnormality in chronic fatigue syndrome. <i>NeuroImage: Clinical</i> , 2018, 20, 102-109.	2.7	29
14	Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. <i>Molecular Medicine</i> , 2018, 24, 44.	4.4	29
15	A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID). <i>BMC Neurology</i> , 2019, 19, 207.	1.8	29
16	Serum Immune Proteins in Moderate and Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients. <i>International Journal of Medical Sciences</i> , 2015, 12, 764-772.	2.5	28
17	Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. <i>Frontiers in Immunology</i> , 2019, 10, 2545.	4.8	22
18	Anabolic androgenic steroids effects on the immune system: a review. <i>Open Life Sciences</i> , 2009, 4, 19-33.	1.4	21

#	ARTICLE	IF	CITATIONS
19	The Economic Impacts of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in an Australian Cohort. <i>Frontiers in Public Health</i> , 2020, 8, 420.	2.7	21
20	A systematic review of metabolomic dysregulation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis/Systemic Exertion Intolerance Disease (CFS/ME/SEID). <i>Journal of Translational Medicine</i> , 2020, 18, 198.	4.4	20
21	Single nucleotide polymorphisms and genotypes of transient receptor potential ion channel and acetylcholine receptor genes from isolated B lymphocytes in myalgic encephalomyelitis/chronic fatigue syndrome patients. <i>Journal of International Medical Research</i> , 2016, 44, 1381-1394.	1.0	19
22	Mapping of pathological change in chronic fatigue syndrome using the ratio of T1- and T2-weighted MRI scans. <i>NeuroImage: Clinical</i> , 2020, 28, 102366.	2.7	19
23	Diffusion tensor imaging reveals neuronal microstructural changes in myalgic encephalomyelitis/chronic fatigue syndrome. <i>European Journal of Neuroscience</i> , 2021, 54, 6214-6228.	2.6	18
24	A targeted genome association study examining transient receptor potential ion channels, acetylcholine receptors, and adrenergic receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. <i>BMC Medical Genetics</i> , 2016, 17, 79.	2.1	17
25	Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 687806.	4.8	17
26	Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients. <i>Journal of Translational Medicine</i> , 2019, 17, 401.	4.4	13
27	A Preliminary Comparative Assessment of the Role of CD8+ T Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis. <i>Journal of Immunology Research</i> , 2016, 2016, 1-8.	2.2	12
28	Reduced glycolytic reserve in isolated natural killer cells from Myalgic encephalomyelitis/chronic fatigue syndrome patients: A preliminary investigation. <i>Asian Pacific Journal of Allergy and Immunology</i> , 2019, 37, 102-108.	0.4	11
29	A systematic review of nutraceutical interventions for mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome. <i>Journal of Translational Medicine</i> , 2021, 19, 81.	4.4	9
30	The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP2 and NK cell function in myalgic encephalomyelitis/chronic fatigue syndrome patients. <i>Journal of Translational Medicine</i> , 2021, 19, 306.	4.4	9
31	Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients. <i>Journal of Translational Medicine</i> , 2022, 20, 94.	4.4	8
32	Network Analysis of Symptoms Co-Occurrence in Chronic Fatigue Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10736.	2.6	7
33	Impact of Life Stressors on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Symptoms: An Australian Longitudinal Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10614.	2.6	6
34	Volumetric differences in hippocampal subfields and associations with clinical measures in myalgic encephalomyelitis/chronic fatigue syndrome. <i>Journal of Neuroscience Research</i> , 2022, 100, 1476-1486.	2.9	6
35	Severity Scales for Use in Primary Health Care to Assess Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. <i>Health Care for Women International</i> , 2016, 37, 671-686.	1.1	5
36	Epidemiology of paediatric chronic fatigue syndrome in Australia. <i>Archives of Disease in Childhood</i> , 2019, 104, 733-738.	1.9	5

#	ARTICLE	IF	CITATIONS
37	Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Healthcare (Switzerland), 2021, 9, 568.	2.0	5
38	Alteration of Cortical Volume and Thickness in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Frontiers in Neuroscience, 2022, 16, 848730.	2.8	5
39	Novel characterisation of mast cell phenotypes from peripheral blood mononuclear cells in chronic fatigue syndrome/myalgic encephalomyelitis patients. Asian Pacific Journal of Allergy and Immunology, 2017, 35, 75-81.	0.4	4
40	Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation. BMC Pharmacology & Toxicology, 2018, 19, 12.	2.4	3
41	Potential Implications of Mammalian Transient Receptor Potential Melastatin 7 in the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Review. International Journal of Environmental Research and Public Health, 2021, 18, 10708.	2.6	3
42	A preliminary investigation of nutritional intake and supplement use in Australians with myalgic encephalomyelitis/chronic fatigue syndrome and the implications on health-related quality of life. Food and Nutrition Research, 2021, 65, .	2.6	2
43	Investigation of mast cell toll-like receptor 3 in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Systemic Mastocytosis participants using the novel application of autoMACS magnetic separation and flow cytometry. Asian Pacific Journal of Allergy and Immunology, 2018, 36, 257-264.	0.4	2
44	Characterization of IL-2 Stimulation and TRPM7 Pharmacomodulation in NK Cell Cytotoxicity and Channel Co-Localization with PIP2 in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. International Journal of Environmental Research and Public Health, 2021, 18, 11879.	2.6	2
45	Sudden infant death syndrome: Postulated role of impaired vasoactive neuropeptide-related inflammatory modulation. Journal of Pediatric Infectious Diseases, 2015, 05, 027-035.	0.2	1
46	Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry. BMC Immunology, 2019, 20, 14.	2.2	1
47	Title is missing!. , 2020, 15, e0232475.		0
48	Title is missing!. , 2020, 15, e0232475.		0
49	Title is missing!. , 2020, 15, e0232475.		0
50	Title is missing!. , 2020, 15, e0232475.		0
51	Title is missing!. , 2020, 15, e0232475.		0
52	Title is missing!. , 2020, 15, e0232475.		0